{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:28:09Z","timestamp":1781656089509,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Eli Lilly"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal\/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Biologic-na\u00efve (COAST-V) or TNF inhibitor-experienced (COAST-W) adults with active r-axSpA received 80\u2009mg ixekizumab every 2\u2009weeks (IXEQ2W) or 4\u2009weeks (IXEQ4W) or PBO or active reference [40\u2009mg adalimumab every 2 weeks (ADAQ2W) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned and patients receiving PBO or ADA were rerandomized 1:1 to IXEQ2W or IXEQ4W through week 52. Assessment of SpondyloArthritis international Society 40% (ASAS40) response rates were examined by baseline CRP (\u22645 or &amp;gt;5\u2009mg\/l) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI spine inflammation score (&amp;lt;2 or \u22652).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the COAST-V\/W integrated dataset (N\u2009=\u2009567), significantly more patients treated with ixekizumab achieved ASAS40 response at week 16 by CRP \u22645\u2009mg\/l (27% IXEQ4W, P\u2009&amp;lt;\u20090.05; 35% IXEQ2W, P\u2009&amp;lt;\u20090.01 vs 12% PBO), CRP &amp;gt;5\u2009mg\/l (39% IXEQ4W, P\u2009&amp;lt;\u20090.001; 43% IXEQ2W, P\u2009&amp;lt;\u20090.001 vs 17% PBO), SPARCC MRI spine score &amp;lt;2 (40% IXEQ4W P\u2009&amp;lt;\u20090.01, 52% IXEQ2W P\u2009&amp;lt;\u20090.001 vs 16% PBO), and SPARCC MRI spine score \u22652 (44% IXEQ4W P\u2009&amp;lt;\u20090.001, 47% IXEQ2W P\u2009&amp;lt;\u20090.001 vs 19% PBO). ASAS40 response was observed with CRP \u22645\u2009mg\/l and SPARCC MRI spine score &amp;lt;2 with IXEQ4W (29%) and was significant with IXEQ2W (48%; P\u2009&amp;lt;\u20090.05) vs PBO (13%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Ixekizumab demonstrated efficacy in the treatment of AS\/r-axSpA in patients with and without elevated CRP or evidence of spinal inflammation on MRI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov): NCT02696785, NCT02696798<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac104","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T12:08:36Z","timestamp":1645099716000},"page":"4324-4334","source":"Crossref","is-referenced-by-count":21,"title":["Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Seem","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir J","family":"Geneus","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurisu","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Ruhr-University Bochum , Bochum"},{"name":"Rheumazentrum Ruhrgebiet , Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University , Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S","family":"Gensler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of California, San Francisco, School of Medicine , San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"2022110207592947900_keac104-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"2022110207592947900_keac104-B2","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.20990","article-title":"The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?","volume":"52","author":"Rudwaleit","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022110207592947900_keac104-B4","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"2022110207592947900_keac104-B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"Elewaut","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2022110207592947900_keac104-B7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1759720X09359728","article-title":"Anti-TNF therapy in ankylosing spondylitis: insights for the clinician","volume":"2","author":"Coates","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022110207592947900_keac104-B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B11","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B12","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.24838","article-title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis","volume":"61","author":"de Vries","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B14","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3899\/jrheum.160003","article-title":"Serum C-reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab","volume":"43","author":"Braun","year":"2016","journal-title":"J Rheumatol"},{"key":"2022110207592947900_keac104-B15","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"2022110207592947900_keac104-B17","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2022110207592947900_keac104-B18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022110207592947900_keac104-B20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2022110207592947900_keac104-B21","first-page":"ii1","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68(Suppl 2","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022110207592947900_keac104-B22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1553-2712.2008.00192.x","article-title":"Availability and quality of computed tomography and magnetic resonance imaging equipment in U.S. emergency departments","volume":"15","author":"Ginde","year":"2008","journal-title":"Acad Emerg Med"},{"key":"2022110207592947900_keac104-B26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.33453","article-title":"Ten years\u2019 experience with needle biopsy in the early diagnosis of sacroiliitis","volume":"64","author":"Gong","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B27","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1002\/art.37695","article-title":"Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents","volume":"64","author":"Richter","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022110207592947900_keac104-B28","doi-asserted-by":"crossref","first-page":"19317","DOI":"10.1073\/pnas.1105857108","article-title":"Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells","volume":"108","author":"Baschant","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022110207592947900_keac104-B29","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/ar4464","article-title":"Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers","volume":"16","author":"Wei\u00df","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac104\/42971543\/keac104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4324\/46747644\/keac104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4324\/46747644\/keac104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T08:01:21Z","timestamp":1667376081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/11\/4324\/6533499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac104","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,2,21]]}}}